CN101675041A - 用作激酶抑制剂的氨基嘧啶类化合物 - Google Patents

用作激酶抑制剂的氨基嘧啶类化合物 Download PDF

Info

Publication number
CN101675041A
CN101675041A CN200880014717A CN200880014717A CN101675041A CN 101675041 A CN101675041 A CN 101675041A CN 200880014717 A CN200880014717 A CN 200880014717A CN 200880014717 A CN200880014717 A CN 200880014717A CN 101675041 A CN101675041 A CN 101675041A
Authority
CN
China
Prior art keywords
compound
substitution
alkyl
cancer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880014717A
Other languages
English (en)
Chinese (zh)
Inventor
H·宾奇
S·扬
C·戴维斯
M·莫蒂默尔
J·戈莱克
J·斯塔德利
D·罗宾逊
M·奥丹尼尔
D·伯雅尔
J·宾德
S·艾弗里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101675041A publication Critical patent/CN101675041A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880014717A 2007-03-20 2008-03-19 用作激酶抑制剂的氨基嘧啶类化合物 Pending CN101675041A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91901407P 2007-03-20 2007-03-20
US60/919,014 2007-03-20
US94677807P 2007-06-28 2007-06-28
US60/946,778 2007-06-28
PCT/US2008/057465 WO2008115973A2 (en) 2007-03-20 2008-03-19 Aminopyrimidines useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN101675041A true CN101675041A (zh) 2010-03-17

Family

ID=39743123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014717A Pending CN101675041A (zh) 2007-03-20 2008-03-19 用作激酶抑制剂的氨基嘧啶类化合物

Country Status (8)

Country Link
US (1) US20100137305A1 (https=)
EP (1) EP2142537A2 (https=)
JP (2) JP2010522194A (https=)
CN (1) CN101675041A (https=)
AU (1) AU2008228963A1 (https=)
CA (1) CA2682195A1 (https=)
MX (1) MX2009010037A (https=)
WO (1) WO2008115973A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024246A (zh) * 2012-03-27 2014-09-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MX2008005814A (es) * 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2668429A1 (en) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
ES2347721T3 (es) 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
EP2137183B1 (en) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
AU2008226457B2 (en) 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008115973A2 (en) * 2007-03-20 2008-09-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
CA2694381A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
KR20110131302A (ko) * 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
JP2012521426A (ja) * 2009-03-24 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US9382229B2 (en) * 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
WO2016166604A1 (en) * 2015-04-17 2016-10-20 Ludwig Institute For Cancer Research Ltd Plk4 inhibitors
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
PE20210455A1 (es) * 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6846928B2 (en) * 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2008115973A2 (en) * 2007-03-20 2008-09-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024246A (zh) * 2012-03-27 2014-09-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Also Published As

Publication number Publication date
MX2009010037A (es) 2009-11-05
JP2010522194A (ja) 2010-07-01
AU2008228963A1 (en) 2008-09-25
WO2008115973A2 (en) 2008-09-25
CA2682195A1 (en) 2008-09-25
WO2008115973A3 (en) 2008-12-04
EP2142537A2 (en) 2010-01-13
US20100137305A1 (en) 2010-06-03
JP2013237703A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
CN101675041A (zh) 用作激酶抑制剂的氨基嘧啶类化合物
JP7317878B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP7028861B2 (ja) ピリジル置換のインドール化合物
CN107501274B (zh) 可用作atr激酶抑制剂的化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
IL291901A (en) Bicyclic heterocycles as fgfr inhibitors
JP6424224B2 (ja) 新規ビスアミドピリジン
CN109422754A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN109890819A (zh) 作为免疫调节剂的杂环化合物
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN101772500A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN101952286A (zh) 用于治疗和雄激素受体有关的病症的双环衍生物
JP2009515882A (ja) プロテインキナーゼを阻害するための方法
JP2016512239A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN101679378A (zh) 用作激酶抑制剂的噻唑和吡唑
CN104334557A (zh) 二酰基甘油酰基转移酶2抑制剂
CN101687852A (zh) 可用作激酶抑制剂的噻唑类和吡唑类化合物
JP2016512815A (ja) Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
TW201718534A (zh) ３－胺基－１，５，６，７－四氫－４ｈ－吲哚－４－酮
CN101321759A (zh) 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
JP2013082757A (ja) プロテインキナーゼ阻害薬として有用なベンズイミダゾール
TW202227431A (zh) 可做為tlr9抑制劑之經取代雜芳基化合物
WO2022155941A1 (en) Cdk2 inhibitors
CN120981448A (zh) 含氮大环类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1138573

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100317

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1138573

Country of ref document: HK